Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Net Cash Flow: 2017-2025

Historic Net Cash Flow for Denali Therapeutics (DNLI) over the last 9 years, with Sep 2025 value amounting to -$50.2 million.

  • Denali Therapeutics' Net Cash Flow fell 414.87% to -$50.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 103.24%. This contributed to the annual value of $47.9 million for FY2024, which is 152.67% up from last year.
  • According to the latest figures from Q3 2025, Denali Therapeutics' Net Cash Flow is -$50.2 million, which was down 159.63% from $84.3 million recorded in Q2 2025.
  • In the past 5 years, Denali Therapeutics' Net Cash Flow ranged from a high of $99.4 million in Q4 2022 and a low of -$188.5 million during Q1 2022.
  • Moreover, its 3-year median value for Net Cash Flow was $14.1 million (2024), whereas its average is -$11.4 million.
  • Per our database at Business Quant, Denali Therapeutics' Net Cash Flow skyrocketed by 503.37% in 2024 and then crashed by 414.87% in 2025.
  • Quarterly analysis of 5 years shows Denali Therapeutics' Net Cash Flow stood at -$101.1 million in 2021, then skyrocketed by 198.37% to $99.4 million in 2022, then crashed by 121.03% to -$20.9 million in 2023, then spiked by 503.37% to $84.3 million in 2024, then tumbled by 414.87% to -$50.2 million in 2025.
  • Its last three reported values are -$50.2 million in Q3 2025, $84.3 million for Q2 2025, and -$116.5 million during Q1 2025.